Tomohiro Kaneta

ORCID: 0000-0003-1146-5092
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Medical Imaging Techniques and Applications
  • Cancer, Hypoxia, and Metabolism
  • Radiomics and Machine Learning in Medical Imaging
  • Radiopharmaceutical Chemistry and Applications
  • Cardiac Imaging and Diagnostics
  • Advanced MRI Techniques and Applications
  • Renal cell carcinoma treatment
  • Lung Cancer Diagnosis and Treatment
  • Moyamoya disease diagnosis and treatment
  • Medical Imaging and Pathology Studies
  • Pancreatic and Hepatic Oncology Research
  • Advanced X-ray and CT Imaging
  • Intracranial Aneurysms: Treatment and Complications
  • Dementia and Cognitive Impairment Research
  • Lung Cancer Research Studies
  • MRI in cancer diagnosis
  • Advanced Radiotherapy Techniques
  • Neuroendocrine Tumor Research Advances
  • Cerebrovascular and Carotid Artery Diseases
  • Neurological Complications and Syndromes
  • Nanoplatforms for cancer theranostics
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Chemotherapy-induced cardiotoxicity and mitigation
  • Advanced Neuroimaging Techniques and Applications
  • Cancer Genomics and Diagnostics

Tohoku University
2013-2024

Tohoku University Hospital
2005-2024

Komatsu (Japan)
2023

University of Tsukuba
2020-2021

Yokohama City University
2016-2020

GTx (United States)
2019

Osaki Citizen Hospital
2015

Kyoto University
2007-2008

Furukawa Electric (Japan)
2006

Niigata University
2002

To investigate the efficacy and safety of nitroglycerin plus vinorelbine cisplatin in patients with previously untreated stage IIIB/IV non-small-cell lung cancer (NSCLC) as experimental arm for next phase III trial.One hundred twenty NSCLC were randomly assigned to 25 mg/m2 on days 1 8 80 day 1, transdermally applied (25 mg/patient daily 5 days; A) or placebo patch (arm B) every 3 weeks a maximum four cycles double-blind controlled trial. Primary end points best confirmed response rate time...

10.1200/jco.2005.04.0436 article EN Journal of Clinical Oncology 2006-01-31

Background: It remains to be elucidated whether brain activity is altered in takotsubo cardiomyopathy. Methods and Results: We measured cerebral blood flow (CBF) 3 consecutive patients with cardiomyopathy using 99mTc ethyl cysteinate dimmer single photon-emission computed tomography (SPECT) the acute chronic phases. In all patients, CBF was significantly increased hippocampus, brainstem basal ganglia decreased prefrontal cortex phase, which changes subsided phase full recovery of cardiac...

10.1253/circj.cj-13-1276 article EN Circulation Journal 2013-11-28

Abstract Purpose: Nitroglycerin may improve the response to chemotherapy in advanced non–small cell lung cancer. The effects and mechanisms of nitroglycerin on enhancement chemosensitivity docetaxel carboplatin regimen (DCb) patients with adenocarcinoma have not been reported. Experimental Design: Seventeen operable stable angina pectoris were selected investigate immunoreactivity for hypoxia-inducible factor 1α (HIF-1α), vascular endothelial growth (VEGF), P-glycoprotein (P-gp), production...

10.1158/1078-0432.ccr-06-1124 article EN Clinical Cancer Research 2006-11-15

Moyamoya disease is an idiopathic occlusive cerebrovascular disorder with abnormal microvascular proliferation. We investigated the clinical utility of leptomeningeal high signal intensity (ivy sign) sometimes seen on fluid-attenuated inversion recovery images in disease.We examined relationship between degree ivy sign and severity ischemic symptoms 96 hemispheres 48 patients disease. classified each cerebral hemisphere into 4 regions from anterior to posterior. In 192 24 patients, we...

10.3174/ajnr.a1504 article EN cc-by American Journal of Neuroradiology 2009-02-26

Objectives [ 18 F] Fluorodeoxyglucose positron emission tomography (FDG PET), a standard tool for evaluating malignancies, can also detect inflammatory lesions. However, its usefulness in muscle lesions polymyositis and dermatomyositis syndromes (PM/DM) has not been established. Methods 33 patients with PM/DM who had undergone FDG PET were retrospectively analysed. uptake was visually evaluated (visually identified uptake, vFDG) 16 regions of the body using mediastinum blood vessels as...

10.1136/bmjopen-2014-006763 article EN cc-by-nc BMJ Open 2015-01-01

Various molecular-targeting therapies have become available for the treatment of advanced renal cell carcinoma (RCC). Accurate prognostication is desirable choosing appropriate individual patients. 18F-2-fluoro-2-deoxyglucose positron-emission tomography/computed tomography (FDG PET/CT) a non-invasive tool evaluating glucose accumulation, which can be an index biological characteristics cancer. We prospectively evaluated FDG PET/CT as prognostic indicator in patients with RCC. A total 101...

10.1186/s12885-016-2097-4 article EN cc-by BMC Cancer 2016-02-08

This open-label, non-randomized, phase I study examined the pharmacokinetics (PK) and radiation dosimetry of a single dose radium-223 in Japanese patients with castration-resistant prostate cancer (CRPC) bone metastases. Six male (mean age 72.5 years, range 65–79 years) histologically or cytologically confirmed stage IV adenocarcinoma were recruited. A was delivered intravenously (IV) via slow bolus over 2–5 min period: Cohort 1 received 50 kBq/kg 2 100 kBq/kg. Following injection, rapidly...

10.1007/s12149-016-1093-8 article EN cc-by Annals of Nuclear Medicine 2016-06-07

The purpose of this multicenter study was to evaluate the clinical usefulness positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) for suspected recurrent gastric cancer. We performed a retrospective review 92 consecutive patients who underwent PET [either integrated PET/computed (CT) or manual fusion dedicated and CT] scans post-treatment surveillance cancer between June 2006 December 2007. Of these patients, 46 were recurrence by other imaging modalities (Group A), 19...

10.1093/jjco/hyp010 article EN Japanese Journal of Clinical Oncology 2009-03-05

To analyze voxel-wise correlation between cerebral blood flow (CBF) measured using ASL-MRI and cognition in patients with Alzheimer's disease (AD). Forty-one diagnosed AD or mild cognitive impairment due to were recruited for this study. CBF images obtained (n = 41) a post-labeling delay (PLD) of 1.5 2.5 s (PLD1.5 PLD2.5, respectively) 3 T scanner, addition brain perfusion SPECT N-isopropyl-4-[I-123]iodoamphetamine 28). Voxel-based analyses performed Mini-Mental State Examination (MMSE)...

10.1186/s12883-017-0870-x article EN cc-by BMC Neurology 2017-05-15

Tyrosine-kinase inhibitor (TKI) targeting angiogenesis improves the prognosis of patients with metastatic renal cell carcinoma (RCC), but its effect is temporary. In order to understand mechanism by which RCC acquires resistance TKI, we investigated change glucose accumulation in FDG PET/CT when they demonstrated progression disease (PD) against TKI. We monitored 38 treated TKI 162 sequentially until were judged demonstrate PD. Standardized uptake value (SUV), a simplified index tissue rate,...

10.1186/s12885-016-3044-0 article EN cc-by BMC Cancer 2017-01-09

We reported previously the usefulness of 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) to predict prognosis renal cell carcinoma (RCC) treated with molecular targeted agents. Herein we describe a preliminary research nine patients who underwent FDG-PET/CT before and after initiation nivolumab. Patients metastatic RCC were by nivolumab from October 2016 March 2017 enrolled in this study. All at baseline 1 month as first response assessment,...

10.1186/s12885-019-5510-y article EN cc-by BMC Cancer 2019-04-02

It is well known that hematopoietic cytokine stimulation can cause diffuse increase of FDG accumulation in bone marrow on PET imaging, which simulates seen patients with metastases. However, uptake be caused by other etiologies. We report 2 who did not have a history stimulation. The images showed uptake, and the were diagnosed as having myelodysplastic syndromes. These cases demonstrate suggest neoplastic disease tissues.

10.1097/01.rlu.0000242685.55001.67 article EN Clinical Nuclear Medicine 2006-10-18
Coming Soon ...